Lytic peptide prodrugs

Details Lytic peptide prodrugs Lytic peptide prodrugs

2001-08-27

2008-11-25

Canella, Karen A (Department: 1643)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S012200, C530S300000, C530S324000, C530S402000, C530S820000, C530S822000, C530S825000

Reexamination Certificate

active

07456146

ABSTRACT:
A cytotoxin can be rendered non-toxic by charge neutralizing the amino acids salient to pore assembly and/or sterically inhibiting formation of the peptide's active conformation. In the presence of specific proteases, the inactive peptide or procytotoxin can be activated to assemble into its lytic conformation and selectively destroy a target cell.

REFERENCES:
patent: 5717064 (1998-02-01), Julian et al.
patent: 6255282 (2001-07-01), Jaynes
patent: 6265540 (2001-07-01), Isaacs et al.
patent: 2003/0138432 (2003-07-01), Glazier
patent: WO97/45544 (1997-12-01), None
patent: WO03092632 (2003-11-01), None
Fernandez-Lopez et al (Nature, Jul. 2001, vol. 412, pp. 452-455, 329).
PCT 97/33908 Rivett, et al.
Blondelle et al., “Hemolytic and Antimicrobial Activities of the Twenty-Four Individual Omission Analogues of Melittin,”Biochemistry, 1991, pp. 4671-4678, vol. 30, American Chemical Society.
Dempsey et al., “Contributioon of Proline-14 to the Structure and Actions of Melittin,”FEBS Letters, 1991, pp. 240-244, vol. 281, No. 1,2, Elsevier Science Publishers B.V.
Leippe et al., “Cytolytic and Antibacterial Activity of Synthetic Peptides Derived from amoebapore, the Pore-Forming Peptide ofEntamoeba histolytica,” Proc. Natl. Acad. Sci. USA, 1994, pp. 2602-2606, vol. 91, Federation of European Biochemical Societies.
Andraå et al., “Shortened Amoebapore Analogs with Enhanced Antibacterial and Cytolytic Activity,”FEBS Letters, 1996, pp. 96-100, vol. 385, Federation of European Biochemical Societies.
Shai et al., “Diastereomers of Cytolysins, a Novel Class of Potent Antibacterial Peptides,”Journal Biological Chemistry, 1996, pp. 7305-7308, vol. 271 No. 13, The American Society for Biochemistry and Molecular Biology, Inc.
Werkmeister et al., “The Effect of Sequence Variations and Structure on the Cytolytic Activity of Melittin Peptides,”Biochimica et Biophysica Acta, 1993, pp. 50-54, vol. 1157, Elsevier Science Publishers B.V.
Leippe et al., “Pore-Forming Peptide of PathogenicEntamoeba histolytica,” Proc. Natl. Acad. Sci. USA, 1991, pp. 7659-7663, vol. 88, Federation of European Biochemical Societies.
Horoszewicz et al., “LNCaP Model of Human Prostatic Carcinoma1,”Cancer Research, 1983, pp. 1809-1818, vol. 43, No. 4, American Association for Cancer Research.
Pinto et al., “Prostate Specific Membrane Antigen, a Unique Glutamate Carboxypeptidase: A Review of Recent Findings,”The Prostate Journal, 1999, pp. 15-26, vol. 1, No. 1, Blackwell Science, Inc.
Lopes et al., “Immunohistochemical and Pharmacokinetic Characterization of the Site-Specific Immunoconjugate CYT-356 Derived from Antiprostate Monoclonal Antibody,”Cancer Research, 1990, pp. 6423-6429, vol. 50, American Association for Cancer Research.
Troyer et al., “Detection and Characterization of the Prostate-Specific Membrane Antigen (PSMA) in Tissue Extracts and Body Fluids,”Int. J. Cancer, 1995, pp. 552-558, vol. 62, Wiley-Liss, Inc.
Wallrapp et al., “A Novel Transmembrane Serine Protease (TMPRSS3) Overexpressed in Pancreatice Cancer1,2,”Cancer Research, 2000, pp. 2602-2606, vol. 60, No. 10, American Association for Cancer Research.
Wright et al., “Expression of Prostate-Specific membrane Antigen in Normal, Benign, and Malignant Prostate Tissues,”Urol. Oncol., 1995, pp. 18-28, vol. 1, Elsevier Science Inc., New York.
Praunsnitz et al., “Electroporation of Mammalian Skin: A Mechanism to Enhance Transdermal Drug Delivery”, Proc. Natl. Acad. Sci. USA, 1993, pp. 10504-10508, vol. 90, No. 22, Medical Sciences, NIH.
Wallace et al., “Stand and Deliver: Getting Peptide Drugs into the Body”, Science, 1993, pp. 912-913, vol. 260, American Association for the Advancement of Science.
Andreu et al., “Solid-Phase Synthesis of Cecropin A and Related Peptides”, Proc. Natl. Acad. Sci. USA, 1983, pp. 6475-6479, vol. 80, No. 21, Biochemistry, Biological Science.
Andreu et al., “N-Terminal Analogues of Cecropin A: Synthesis, Antibacterial Activity, and Confromational Properties”, Biochemistry, 1985, pp. 1683-1688, vol. 24, No. 7, American Chemical Society.
Fink et al., “Design, Synthesis and Antibacterial Activity of Cecropin-Like Model Peptides”, Int. J. Peptide Protein Res., 1989, pp. 412-421, vol. 33, No. 6, The Rockefeller University, New York, New York.
Fink et al., “The Chemical Synthesis of Cecropin D and an Analog with Enhanced Antibacterial Activity”, J. of Biological Chemistry, 1989, pp. 6260-6267, vol. 264, No. 11, American Society for Biochemistry and Molecular Biology, Inc. Rockefeller University, New York.
Argiolas et al., “Bombolitins, a New Class of Mast Cell Degranulating Peptides from the Venom of the Bumblebee Megabombus Pennsylvanicus”, J. of Biological Chemistry, 1985, pp. 1437-1444, vol. 260, No. 3, American Society of Biological Chemists, Inc.
Young et al., “Characterization of a Member Pore-Forming Protein FromEntamoeba histolytica”, J. Exp. Med. 1982, pp. 1677-1690, vol. 156, No. 6, The Rockefeller University Press.
Lynch et al., “An Ion-Channel Forming Protein Produced byEntamoeba histolytica”, The EMBO Journal, 1982, pp. 801-804, vol. 1, No. 7, IRL Press Limited, Oxford, England.
Young et al., “Molecular Mechanisms of Cytotoxicity Mediated byEntamoeba histolytica: Characterization of a Pore-Forming Protein (PFP)”, J. of Cellular Biochemistry, 1985, pp. 299-308, vol. 29 No. 4, Alan R. Liss, Inc.
Rosenberg et al., “Isolation, Characterization and Partial Purification of a Transferable Membrane Channel (Amoebapore) Produced byEntamoeba histolytica”, Molecular and Biochemical Parasitology, 1989, pp. 237-248, vol. 33, No. 3, Elsevier Science Publishers B.V.
Jansson et al., “Coding of Hemolysins Within the Ribosomal RNA Repeat on a Plasmid inEntamoeba histolytica”, Science, 1994, pp. 11440-11443, vol. 263, American Association for the Advancement of Science.
Fernandez-Lopez et al., “Antibacterial Agents Based on the Cyclic D,L-α-Peptide Architecture”, Letters of Nature, 2001, pp. 452-455, vol. 412.
Woodle et al., “Prolonged Systemic Delivery of Peptide Drugs by Long-Circulating Liposomes: Illustration with Vasopression in the Brattleboro Rat”, Pharmaceutical Research, 1992, pp. 260-265, vol. 9, No. 2, Plenum Publishing Corporation.
Huse et al., “Generatio of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda”, Science, 1989, pp. 1275-1281, vol. 246, Research Article.
Coombs et al., “Substrate Specificity of Prostate-Specific Antigen (PSA)”, Chemistry & Biology, 1998, pp. 475-488, vol. 5, No. 9, Research Paper.

Affiliated with

Also associated with

Rating

Lytic peptide prodrugs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lytic peptide prodrugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lytic peptide prodrugs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4041645